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Abstract
A 32-year-old male presented with diarrhoea, mucus and bleeding per rectum. On the basis of
sigmoidoscopy, rectal mesalazine was commenced uneventfully, and subsequently changed to oral
mesalazine due to failure to improve.
He re-presented 4 days later with frequent rigors, lethargy, palpitations and was generally unwell. His
condition settled with conservative management and IV antibiotics.
Oral mesalazine was withheld during the first 24 hours but was recommenced on day 2. After 2
doses he developed rigors, pyrexia, tachycardia and vomiting.
Oral mesalazine was discontinued thereafter and his condition progressively improved. Mesalazine
has not been re-introduced.
Case presentation
A 32-year-old male Caucasian healthcare worker presented
with a 6/52 history of diarrhoea and mucus, and a 2/12
history or bleeding per rectum. He weighed 72.5 kg and
was1.78mtall.Flexiblesigmoidoscopytothemid-sigmoid
colon demonstrated granular mucosa with loss of the
vascular pattern and bleeding into the mucosa. Rectal
biopsies were taken. He was commenced on 4 g of
Mesalazine enema per rectum nightly. He was reviewed
two weeks later but remained symptomatic and oral
mesalazine1.2gthreetimesdailywasinitiatedatthistime.
He re-presented 4 days later with a significant clinical
deterioration. He was febrile with frequent rigors, lethar-
gic, complaining of palpitations and sinusitis. He was
passing 8-10 stools per day with a significant amount of
blood and mucus per rectum. He was on no other
medications aside from the oral mesalazine.
His past medical history consisted of reflux as a child. He
had no known food or drug allergies. His family history
was significant for a maternal aunt with known colitis, a
maternal uncle with ulcerative colitis and a mother with
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on average 15 units of alcohol per week.
On examination his temperature was 38.4°C, he was
tachycardic,rigoringfrequentlyandlookedgenerallyunwell.
He had routine blood tests and blood cultures carried out.
He was subsequently admitted. He was commenced on
IV co-amoxiclav and IV metronidazole. Stool cultures were
sent for culture and sensitivity including Yersinia and
Campylobacter. Both stool and blood cultures were
reported as negative.
Overnight his temperature settled on the antibiotics. The
frequency of bowel motions remained unchanged and his
stools remained blood stained. His C reactive protein and
his erythrocyte sedimentation rate were elevated. Oral
mesalazine was not administered during the first 24 hours
in hospital but was recommenced on the second day as an
in-patient.
After 2 doses of oral mesalazine he developed rigors, high
temperature, tachycardia and two episodes of vomiting.
At the time sepsis was the major consideration but the
possibility of a drug reaction was considered. The
frequency of bowel motions increased to 15 per day.
A second set of blood cultures was performed. He was
commenced on piperacillin/tazobactam 4.5 g IV tds.
A Computed Tomography scan of abdomen with IV and
oral contrast was carried out. This showed a thickened
colonic wall, most marked in the rectum and distal
sigmoid and also in the caecum. Some linear atelectasis
was noted at the left lung base. These appearances were in
keeping with the clinical diagnosis of a colitis with the
distribution suggestive of a pancolitis most probably
ulcerative colitis. IV hydrocortisone was commenced.
Oral mesalazine was discontinued after the second dose
and he felt better post withdrawal of mesalazine. Both sets
of blood cultures were provisionally reported as negative
at this time. His clinical condition began to improve.
IV hydrocortisone was commenced on the fourth day
of hospitalisation. 2 days later he was switched to oral
prednisolone. He was discharged 3 days later on oral
prednisolone.
As the oral steroids tapered he was started on azathioprine
with stepwise augmentation of dose. His colitis reactivated
and infliximab was introduced. He responded to inflix-
imab and three months later infliximab was discontinued.
He is currently well on azathioprine 150 mg orally once
daily and iron once daily in oral liquid form. Mesalazine
has not been re-introduced.
Discussion
The rigors and general deterioration developed after the
commencement of oral mesalazine. These ceased after
mesalazine was withdrawn and recurred within hours of
re-initiation of mesalazine. While it is possible that the
pyrexia and rigors were related to an underlying sepsis
there was no evidence of an abscess on the CT scan. Blood
and stool cultures were negative. To confirm that the
mesalazine was the cause of the fever it would be necessary
to readminister a dose of the mesalazine. Neither the
patient nor the physician felt that this was justified.
The 5-Aminosalicylates are important agents in the
therapy of ulcerative colitis [1]. There is no advantage of
mesalazine over sulfasalazine for serious adverse reactions
[2]. Salicylate intolerance occurs in 2-7% of patients [3].
Gonzalo et al. report a case similar to ours where a patient
who developed a fever response to mesalazine was
successfully treated with a desensitizing programme to
mesalazine with escalating doses to therapeutic level [4].
The natural history of ulcerative colitis is that of a chronic,
lifelong condition with acute flare-ups and recovery.
Intravenous corticosteroids are still the agent of choice
in the treatment of an acute exacerbation of ulcerative
colitis and the 5-aminosalicylates are normally the
mainstay of treatment in the maintenance of remission
in ulcerative colitis [5]. Azathioprine fulfils this role in this
case due to the adverse reaction experienced by our patient
to 5-ASA’s.
Other options for treatment in the acute phase include
cyclosporine-A (CsA) although toxicity and the need for
monitoring limit its use [6]. Recent advances in the
understanding of the pathophysiology of inflammatory
bowel disease have led to the development of a number of
biological agents, of which infliximab, a monoclonal
antibody to tumour necrosis factor alpha (TNF-a) was the
first to be clinically available. Infliximab has a role both as
an agent to maintain remission and as a rescue therapy in
steroid-refractory disease [7]. For patients who remain
refractory to all of these agents panproctocolectomy with
or without reconstructive surgery will effect a cure but is
not without its own complications [8].
The link between colitis and colorectal neoplasia is well
established. In the long term our patient will require
regular surveillance colonoscopy. There is a paucity of
research on the long-term implications or cancer risk in
patients in whom long-term 5-ASA therapy is not possible.
The use of anti-inflammatory medications have been
demonstrated to have a proven benefit to inhibiting the
development of neoplastic lesions in animal models
however this requires further work in-vivo [9]. Screening
guidelines in UC are well established with a
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commence at 10 years from diagnosis [10].
Conclusion
WhileallergicresponsestoMesalazinearerareitisimportant
to be aware that it is a potential cause of unexplained fever
in patients with inflammatory bowel disease with no focus
of infection.
Abbreviation
CT, computed tomography.
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